Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma

Blood

Volumn 115, Issue 19, 2010, Pages 3960-3965

  Stern, Martin ^a   Opelz, Gerhard ^b   Döhler, Bernd ^b   Hess, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FC GAMMA RECEPTOR 3A; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; NATURAL KILLER CELL RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; FCGR3A PROTEIN, HUMAN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KIR2DS2 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GRAFT RECIPIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ADULT; AGED; CHILD; COHORT ANALYSIS; GENETICS; GENOTYPE; HEART TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENOTYPE; HEART TRANSPLANTATION; HUMANS; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; LIVER TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; RECEPTORS, KIR; RECEPTORS, KIR3DL2; SURVIVAL RATE; YOUNG ADULT;

EID: 77952993021     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-250134     Document Type: Article

References (28)

1. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222-230. (Pubitemid 38248525)
2. Brouwer RM, Balk AH, Weimar W. Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load. Transpl Int. 1992;5(suppl 1):S259-S261.
3. Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol. 2007;17(3):203-210. (Pubitemid 46304228)
4. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100(5):1059-1070. (Pubitemid 27386289)
5. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and eventfree survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005;16(10):1675-1682. (Pubitemid 41510143)
6. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(3):474-481. (Pubitemid 46224224)
7. Stern M, Elsasser H, Honger G, Steiger J, Schaub S, Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant. 2008;8(6):1312-1317. (Pubitemid 351763694)
8. Stewart CA, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102(37):13224-13229. (Pubitemid 41325005)
9. Wheless SA, Gulley ML, Raab-Traub N, et al. Posttransplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med. 2008;178(10):1060-1065.
10. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2006;132(3):326-332. (Pubitemid 43381539)
11. Lee TC, Savoldo B, Barshes NR, et al. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of posttransplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006;20(3):389-393. (Pubitemid 43880577)
12. Babel N, Vergopoulos A, Trappe RU, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation. 2007;84(3):387-391. (Pubitemid 47258328)
13. Hatta K, Morimoto A, Ishii E, et al. Association of transforming growth factor-beta1 gene polymorphism in the development of Epstein-Barr virus-related hematologic diseases. Haematologica. 2007;92(11):1470-1474. (Pubitemid 350144121)
14. Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol. 2009;29(3):316-320.
15. Alarcon GS, McGwin G Jr, Petri M, et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med. 2006;3(10):e396. (Pubitemid 44721834)
16. Norman PJ, Stephens HA, Verity DH, Chandanayingyong D, Vaughan RW. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics. 2001;52(3-4):195-205. (Pubitemid 32142806)
17. Van Dyke AL, Cote ML, Wenzlaff AS, Land S, Schwartz AG. Cytokine SNPs: comparison of allele frequencies by race and implications for future studies. Cytokine. 2009;46(2):236-244.
18. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β 1 gene polymorphisms. Transpl Immunol. 1999;7(2):127-128. (Pubitemid 29472075)
19. Vilches C, Castano J, Gomez-Lozano N, Estefania E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens. 2007;70(5):415-422. (Pubitemid 47537402)
20. Frohn C, Schlenke P, Ebel B, Dannenberg C, Bein G, Kirchner H. DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J Immunol Methods. 1998;218(1-2):155-160. (Pubitemid 28500142)
21. Picard RR, Berk KN. Data splitting. Am Stat. 1990;44(2):140-147.
22. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of posttransplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet. 1999;354(9191):1698-1699. (Pubitemid 29533063)
23. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet. 2005;365(9478):2216-2224. (Pubitemid 40853915)
24. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685):872- 874.
25. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. FcgammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgammaRIIIa, independently of the FcgammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109-1114. (Pubitemid 27314146)
26. Lee YH, Ji JD, Song GG. Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis. J Rheumatol. 2008;35(11):2129-2135.
27. Brown EE, Fallin MD, Goedert JJ, et al. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. Cancer Epidemiol Biomarkers Prev. 2005;14(3):633-637.
28. Estefania E, Gomez-Lozano N, Portero F, et al. Influence of KIR gene diversity on the course of HSV-1 infection: resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2. Tissue Antigens. 2007;70(1):34-41. (Pubitemid 46890276)